Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal ...
Biogen Sued by Neuroscience Company Sage After Buyout Offer (1)
Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $10.53 Consensus Target Price from Analysts
Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned a consensus rating of “Hold” from the ...
Zacks.com on MSN3d
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?
Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...
SchaeffersResearch.com4d
Sage Therapeutics Stock Headed for Best Day in 5 Years
Today's sure has SAGE on track for its largest single-day percentage gain since January 2019. Though further removed from ...
Business Wire6d
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has ...
bovnews4d
Sage Therapeutics (SAGE) Makes Bold Moves: What’s in Store for Investors?
Sage Therapeutics, Inc. (Nasdaq: SAGE) saw its stock price soar by an impressive 33.87%, reaching $7.43 during Monday’s premarket trading session. The surge came on the heels of the company’s ...
SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial
In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...
Sage Therapeutics shares spike after Biogen offers to buy remaining stake
Investing.com - Shares in Sage Therapeutics (NASDAQ: SAGE) were more than 36% higher in premarket US trading on Monday, ...
1SAGE, BIIB : Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy:...
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's ...
Hold Rating for SAGE Therapeutics Amid Biogen Acquisition Offer and Pipeline Challenges
Morgan Stanley analyst Vikram Purohit has maintained their neutral stance on SAGE stock, giving a Hold rating on January 7.Stay Ahead of the ...